New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 28, 2012
06:01 EDTACTG, BSXAcacia Research unit enters into settlement agreement with Boston Scientific
Acacia Research Corporation (ACTG) announced that its Body Science LLC subsidiary has entered into a settlement agreement with Boston Scientific Corporation (BSX). The agreement resolves litigation that was pending in the United States District Court for the District of Minnesota.
News For ACTG;BSX From The Last 14 Days
Check below for free stories on ACTG;BSX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 22, 2014
09:30 EDTBSXBoston Scientific begins trial of ACUITY X4 LV pacing leads
Boston Scientific has conducted the first implant in the clinical trial of the next generation ACUITY X4 left-ventricular pacing leads and RELIANCE™ 4-FRONT defibrillation leads. The clinical trial is designed to establish the safety and effectiveness of both lead families and is intended to support U.S. Food and Drug Administration approval of these devices.
April 21, 2014
09:21 EDTACTGOn The Fly: Pre-Market Movers
HIGHER: Sarepta (SRPT), up 54% after announcing plans to to submit NDA for Eteplirsen by year end 2014. Shares of Prosnesa (RNA), another drugmaker working on a competing DMD drug, are up more than 12%... AstraZeneca (AZN), up 6% after the Sunday Times says that Pfizer (PFE) is considering a takeover bid for the company. Pfizer is up 1.2% following the report... Newmont Mining (NEM), up 8% after WSJ says the company and Barrick Gold (ABX) could resume merger talks as soon as today... Cbeyond (CBEY), up 39% after agreeing to be acquired for about $323M by Birch Communications... Momenta Pharma (MNTA), up 10.5% after the Supreme Court rejected Teva's (TEVA) bid to delay generic Copaxone... Nu Skin (NUS), up 5% after saying its China division will resume corporate-hosted business meetings... Micron (MU), up 4% after price target raised at Drexel Hamilton... DOWN AFTER EARNINGS: Acacia Research (ACTG), down 6%... athenahealth (ATHN), down 5.6%.
09:00 EDTACTGAcacia Research falls 7.6%
Subscribe for More Information
April 17, 2014
16:02 EDTACTGAcacia Research reports Q1 adjusted EPS (11c), may not compare consensus 4c
Subscribe for More Information
15:29 EDTACTGNotable companies reporting after market close
Notable companies reporting before tomorrow's market open, with earnings consensus, include athenahealth (ATHN), consensus 17c; Allison Transmission (ALSN), consensus 31c; Investors Bancorp (ISBC), consensus 24c; Cepheid (CPHD), consensus (17c); Advanced Micro Devices (AMD), consensus 0c; Associated Banc-Corp (ASBC), consensus 25c; Hub Group (HUBG), consensus 36c; Capital Bank (CBF), consensus 24c; Select Comfort (SCSS), consensus 32c; Acacia Research (ACTG), consensus 4c.
April 16, 2014
15:39 EDTBSXBoston Scientific CRT-D approval neutral for St. Jude, says Wells Fargo
Subscribe for More Information
06:03 EDTACTGAcacia Research subsidiary signs patent license agreement with Samsung
Acacia Research's Saint Lawrence Communications subsidiary has entered into a settlement and patent license agreement with Samsung Electronics. The agreement resolves litigation that was pending in the United States District Court for the Eastern District of Texas.
April 15, 2014
16:47 EDTBSXBoston Scientific announces FDA approval for defibrillators
Subscribe for More Information
11:53 EDTBSXVascular Solutions: Injunction against Boston Scientific's Guidezilla vacated
Subscribe for More Information
09:23 EDTBSXBarclays medical supplies/devices analysts hold analyst/industry conference call
Subscribe for More Information
06:06 EDTACTGAcacia Research's subsidiary partners with semiconductor company
Subscribe for More Information
April 14, 2014
10:02 EDTBSXOn The Fly: Analyst Upgrade Summary
Acorda Therapeutics (ACOR) upgraded to Outperform from Market Perform at FBR Capital... Allegheny Technologies (ATI) upgraded to Neutral from Underperform at Sterne Agee... BP (BP) upgraded to Buy from Hold at Canaccord... Bloomin' Brands (BLMN) upgraded to Buy from Hold at Deutsche Bank... Boardwalk Pipeline (BWP) upgraded to Neutral from Underperform at BofA/Merrill... Boston Scientific (BSX) upgraded at BofA/Merrill... Charles Schwab (SCHW) upgraded to Buy from Neutral at UBS... Citigroup (C) upgraded to Hold from Sell at Rafferty Capital... Community Health (CYH) upgraded to Outperform from Perform at Oppenheimer... Eaton Vance (EV) upgraded to Neutral from Sell at Citigroup... Eli Lilly (LLY) upgraded to Hold from Underperform at Jefferies... F5 Networks (FFIV) upgraded to Buy from Hold at Stifel... HeartWare (HTWR) upgraded to Buy from Neutral at BTIG... Heartland Payment (HPY) upgraded to Hold from Sell at Stifel... Hyatt Hotels (H) upgraded to Outperform from Market Perform at FBR Capital... MasterCard (MA) upgraded to Outperform from Neutral at RW Baird... McDermott (MDR) upgraded to Neutral from Underweight at HSBC... Palo Alto (PANW) upgraded to Overweight at Stephens... PetroChina (PTR) upgraded to Neutral from Underperform at Credit Suisse... Seagate (STX) upgraded to Buy from Hold at Argus... Sensata (ST) upgraded to Buy from Neutral at Citigroup... Stryker (SYK) upgraded to Neutral from Reduce at SunTrust... TD Ameritrade (AMTD) upgraded to Buy from Neutral at UBS... TTM Technologies (TTMI) upgraded to Buy from Hold at Stifel... Transocean (RIG) upgraded to Hold from Sell at Deutsche Bank... VMware (VMW) upgraded to Outperform from Underperform at CLSA... Visa (V) upgraded to Outperform from Neutral at RW Baird... Yahoo (YHOO) upgraded to Buy from Neutral at SunTrust... Zimmer (ZMH) upgraded to Neutral from Reduce at SunTrust... bebe stores (BEBE) upgraded to Buy from Neutral at Janney Capital.
06:44 EDTBSXBoston Scientific upgraded at BofA/Merrill
As previously reported, BofA/Merrill upgraded Boston Scientific to Buy from Neutral. The firm upgraded shares given increased confidence in the pipeline, opportunities to increase margin, valuation, and expectations the FDA will approve the LAA product this year. Price target raised to $16.
06:18 EDTBSXBoston Scientific upgraded to Buy from Neutral at BofA/Merrill
Price target is $16.
April 10, 2014
18:34 EDTBSXBoston Scientific enrolls first patient in registry for evaluating Vercise DBS
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use